Citizens JMP Reiterates Market Perform Rating on Athira Pharma (ATHA)

Citizens JMP analyst Jason Butler reiterated a Market Perform rating on Athira Pharma (NASDAQ: ATHA).

The analyst commented, “On track to dose ALS patients in late-2025; we reiterate our Market Perform rating on Athira Pharma. On Friday afternoon, Athira reported 1Q25 financial results and provided a business update as the company continues to focus on ATH-1105 development for amyotrophic lateral sclerosis (ALS) treatment. The company intends to initiate a biomarker-focused study in ALS patients in late-2025. Athira ended the quarter with ~$37MM in cash; we think the current valuation (~27% of cash) represents a fair discount, consistent with biopharma peers facing similar uncertainty.”

For an analyst ratings summary and ratings history on Athira Pharma click here. For more ratings news on Athira Pharma click here.

Shares of Athira Pharma closed at $0.25 yesterday.

You May Also Be Interested In

• Eikon Therapeutics, Inc. (EIKN) Misses Q2 EPS by 163c
• Lument Finance Trust (LFT) Misses Q2 EPS by 17c
• Gemini Space Station, Inc. (GEMI) Misses Q2 EPS by 32c